Trial Profile
An Open Label, Multicentre, Two Stage, Phase II Study To Evaluate Efficacy And Safety Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs P 276 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ENVER
- Sponsors Piramal Enterprises
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry.)